Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 11/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 4/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.39 |
| ▸ | PER2 | O15055 | 1/20 | 0.36 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.36 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.36 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1100381 | 0.85 | PTGES (0.52) | TRPM8PTGESALOX5 | |
| SCHEMBL1099414 | 0.83 | PTGES (0.58) | TRPM8PTGESALOX5 | |
| SCHEMBL1099039 | 0.83 | PTGES (0.55) | TRPM8PTGESALOX5 | |
| SCHEMBL1100098 | 0.82 | PTGES (0.59) | TRPM8PTGESALOX5 | |
| SCHEMBL1099652 | 0.81 | PTGES (0.48) | TRPM8PTGESALOX5 | |
| SCHEMBL1100475 | 0.79 | TRPM8 (0.47) | TRPM8PTGESALOX5 | |
| SCHEMBL1098464 | 0.79 | TRPM8 (0.43) | TRPM8PTGESALOX5 | |
| SCHEMBL1099776 | 0.79 | TRPM8 (0.52) | TRPM8PTGESALOX5 | |
| SCHEMBL1099503 | 0.77 | TRPM8 (0.50) | TRPM8PTGESALOX5 | |
| SCHEMBL1098422 | 0.76 | TRPM8 (0.49) | TRPM8PTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434711-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2016-09-06 | — | — | US | disclosed |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-23 | — | — | US | disclosed |
| US-8809327-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-19 | — | — | US | disclosed |
| EP-2183239-B1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-22 | — | — | EP | disclosed |
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | BRANUM SHAWN T (US) | 2012-07-26 | — | — | US | disclosed |
| US-8153682-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-10 | — | — | US | disclosed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | TRPM8 1/4885MEP1B 1162/4885PTGES 309/4885 |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | TRPM8 1/4885MEP1B 1162/4885PTGES 309/4885 |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | TRPM8 1/4885MEP1B 1162/4885PTGES 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.